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Available online 6 December 2017Despite tremendous advances in targeted therapies against lung adenocarcinoma, themajority of patients do not
beneﬁt from personalized treatments. A deeper understanding of potential therapeutic targets is crucial to in-
crease the survival of patients. One promising target, ADAR, is ampliﬁed in 13% of lung adenocarcinomas and
in-vitro studies have demonstrated the potential of its therapeutic inhibition to inhibit tumor growth. ADAR
edits millions of adenosines to inosines within the transcriptome, and while previous studies of ADAR in cancer
have solely focused on protein-coding edits, N99% of edits occur in non-protein coding regions. Here, we develop
a pipeline to discover the regulatory potential of RNA editing sites across the entire transcriptome and apply it to
lung adenocarcinoma tumors from The Cancer Genome Atlas. Thismethod predicts that 1413 genes contain reg-
ulatory edits, predominantly in non-coding regions. Genes with the largest numbers of regulatory edits are
enriched in both apoptotic and innate immune pathways, providing a link between these known functions of
ADAR and its role in cancer. We further show that despite a positive association between ADAR RNA expression
and apoptotic and immune pathways, ADAR copy number is negatively associatedwith apoptosis and several im-
mune cell types' signatures.e, Indian
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ADAR1. Introduction
Each year, N500,000 people die from lung adenocarcinoma (LUAD)
globally, and only a minority of these tumors harbor alterations target-
able by existing personalized therapies (Imielinski et al., 2012; Collisson
et al., 2014). Research into targeting new oncogenes is crucial to
expanding the proportion of treatable tumors. The genomic locus con-
taining the adenosine deaminase acting on RNA (ADAR) gene is ampli-
ﬁed in 13% of LUAD and has been functionally conﬁrmed as an
oncogene in lung (Anadón et al., 2015), breast (Fumagalli et al., 2015),
stomach (Chan et al., 2016), chronic myeloid leukemia (Jiang et al.,
2013) and liver (Chen et al., 2013b) cancers. Knockdown of ADAR in
LUAD is associated with reduced in-vitro cell viability, and decreaseda University School of
ly Detection, Stanford
@iu.edu (K. Huang).
n open access article undermetastatic potential in xenograft mouse models (Anadón et al., 2015).
Therefore, targeted therapies towards and a greater functional under-
standing of ADAR ampliﬁed tumors have the potential to greatly in-
crease the number of treatable cases of LUAD.
Adenosine to inosine RNA editing is mediated predominantly by the
ADAR gene and to a lesser extent, the ADARB1 gene. This modiﬁcation
occurs in millions of sites across the transcriptome, mostly within Alu
repeats (Bahn et al., 2015). Previous studies of the oncogenic role of
ADAR in cancer have focused on the editing of coding sequences of
tumor-associated proteins, such as AZIN1 (Chen et al., 2013b) and
NEIL1 (Anadón et al., 2015). Although this role has been conﬁrmed in
functional studies of hepatocellular carcinoma, b1% of known RNA
editing sites reside in coding sequences (Han et al., 2015). The function
of RNA editing in non-protein coding regions is only known for a few
edited genes. For example, it has been shown that ADAR-mediated
RNA editing changes the accessibility to the HuR RNA binding protein
(RBP) within the cathepsin S (CTSS) 3′ UTR, which enhances its mRNA's
stability in endothelial cells (Stellos et al., 2016). In addition, Zhang et al.
showed that RNA editing of theMDM2 3′UTR segment can abolish mir-
200bmediated repression of theMDM2mRNA. Recently, RNA editing ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Mannion et al., 2014; Liddicoat et al., 2015; Pestal et al., 2015; George et
al., 2016) and apoptosis (Yang et al., 2017; Sakurai et al., 2017), but it is
not clear how these functions are related to ADAR's oncogenic potential.
Here, we investigate the role ofmRNA abundance regulation by RNA
editing in human LUAD. We create a pipeline that inputs RNA gene
abundances and RNA editing frequencies, and outputs potentially regu-
latory pairs of RNA editing sites andmRNA target genes. This pipeline is
applied to The Cancer GenomeAtlas (TCGA) LUADRNA sequencing data
to obtain a global picture of the RNA regulatory editome. We identify
enrichment of both apoptosis and immunoregulatory genes potentially
regulated by ADAR-mediated RNA editing. ADAR is alternatively spliced
into two separate isoforms: a short, nuclear, and constitutively
expressed p110 isoform; and a long, cytosplasmic, and interferon induc-
ible p150 isoform (Pestal et al., 2015). The p110 isoform is responsible
for ﬁne tuning apoptosis, at least in part via modulating accessibility
to Staufen 1 binding sites in edited mRNA's (Yang et al., 2017; Sakurai
et al., 2017). The p150 isoform edits double stranded dsRNA's and pre-
vents them from activating the MDA5-MAVS interferon response. Nei-
ther of these functions of ADAR have been linked to cancer, although it
was seen by Fumagalli, et al. that ADAR RNA expression is jointly ex-
plained by ADAR genomic copy number and STAT1 expression, a marker
of interferon activity (Fumagalli et al., 2015). We further establish that
ADAR genomic copy number (CN) is negatively associatedwith immune
and apoptosis pathways, aswell as immune cell signatures, establishing
potential oncogenic roles for ADAR in LUAD.
2. Materials and Methods
2.1. Data
RNAseq abundances, copy number data, and editing frequencies
were downloaded for lung adenocarcinoma (LUAD) matched normal
and tumor samples. RNAseq gene level expression (RNAseqV2 RSEM)
and copy number data were downloaded from Broad Institute Firehose
(https://gdac.broadinstitute.org). Gistic 2.0 copy number data was fur-
ther processed to gene level as follows. If a gene is contained within a
segment as deﬁned in the gistic-processed data, the value of that seg-
ment is assigned to the gene. Editing frequency data was downloaded
from synapse.org (https://www.synapse.org/#!Synapse:syn2374375/
ﬁles/) (Han et al., 2015). Editing frequency is the number of edited
reads covering a given editing site divided by the total number of
reads covering that editing site. Editing sites are annotated in the
RADAR (Ramaswami and Li, 2014) database, which collects and curates
functionally validated A-I RNA editing sites.
2.2. Identiﬁcation of Regulatory Edits
First, RNA editing sites were matched to the genes containing them.
Often, there are multiple RNA editing sites within each gene. Then, for
each gene, RNA editing frequencies were associated to RNA abundances
with spearman correlation. Signiﬁcant edits were determined using R's
(v1.0.136) built in signiﬁcance of correlation test and corrected for mul-
tiple hypothesis testing (Benjamini Hochberg corrected q-value b 0.1).
All correlations performed in this study are spearman correlations.
2.3. RNA Binding Protein and microRNA Motif Analysis and Secondary
Structure Visualization
Regulatory edits were grouped by gene and searched for continu-
ously edited regions (CER). A CER was deﬁned as N5 sequential signiﬁ-
cant RNA regulatory editing sites, with no two consecutive RNA editing
sites being separated by N100 base pairs. These CERswere then input as
a bedﬁle into the RBPmap tool (http://rbpmap.technion.ac.il) (Paz et al.,
2014), which searches for RNA binding protein (RBP) motifs within ge-
nomic regions. We used the following parameters in our searches: highstringency, hg19 reference, all Human/Mouse motifs, and no conserva-
tion ﬁlter. MicroRNA motif enrichment was calculated using the
targetScan web tool (Grimson et al., 2007), and microRNA's with com-
bined score b −0.3 were considered for further analysis. Secondary
structure prediction was made with the Forna (Kerpedjiev et al.,
2015) web app.
2.4. Pathway and Immune Cell Analysis
Pathway scores for tumor sampleswere calculated using single sam-
ple gene set enrichment analysis (SSGSEA) (Barbie et al., 2009). Im-
mune exclusion and tumor purity scores were downloaded from Aran
et al. (2015) and converted to immune inﬁltrate scores (1-SCORE). Im-
mune cell subset analysis was performed using the TIMER web app
(https://cistrome.shinyapps.io/timer/) (Li et al., 2016).
2.5. Histological Slide Evaluation of Immune Cell Subsets
Histological slides for TCGA LUAD tumors, were visualized using the
digital slide archive (http://cancer.digitalslidearchive.net) (Gutman et
al., 2013). We selected a subset of tumors such that there were roughly
equal representation of ADAR ampliﬁed and normal copy numbers. In
total, 97 LUAD tumors, 45 of which had no evidence of ADAR ampliﬁca-
tion, and 52 of which had high ADAR copy number, were selected for
analysis and we conducted the experiment with no knowledge of the
ADAR CN status of these tumors. Wewere able to visually estimate neu-
trophil, lymphocyte, andmacrophage inﬁltrations, aswell as necrosis on
a scale of 0–3.
3. Results
3.1. Pipeline for Discovery of Regulatory A-I RNA Editing Sites
Wecreated a pipeline for discovery of regulatory RNAediting sites as
follows.We ﬁrstmatched each RNA editing site with its host RNA abun-
dance (Fig. 1A), then tested all RNA edits for their association with host
RNA abundance (Fig. 1B–C). All relevant code can be found at github.
com/michaelsharpnack/RNA_edits.
3.2. Landscape of Regulatory Editing Sites in Lung Adenocarcinoma
Previous papers have focused on the potential for protein coding
RNA editing sites to modify oncogene and tumor suppressor func-
tions; however, the frequencies of many non-coding RNA editing
sites are signiﬁcantly increased in LUAD. In the TCGA LUAD cohort,
4115 non-protein-coding RNA editing sites were differentially
edited (t-test, BH q-value b 0.1) while only 20 protein coding RNA
editing sites were differentially edited (Supplementary Fig. 1). We
therefore applied our regulatory RNA editing pipeline to the TCGA
LUAD RNAseq dataset to discover alternative functions of the ADAR
oncogene.
RNAseq data for 488 LUAD tumor and 57 matched normal samples
were run through our regulatory RNA editing pipeline. This data in-
cludes 54,362 frequently edited sites, and 52,276 RNA editing site-
RNA abundance combinations tested for their regulatory potential.
5468 (10%) of the edit-gene combinationswere predicted to have regu-
latory potential across 1413 genes (Fig. 2A). The majority of the signiﬁ-
cant RNA editing sites had a positive association with RNA abundance
(4976 or 91%, Fig. 2B). It is possible that the enrichment of positive
RNA editing-mRNA abundance associations is due to a bias in detection;
given that we would not be able to measure frequently edited tran-
scripts that are degraded. Gene expression and length are both potential
sources of bias in regulatory RNA editing site detection. The expression
of each gene with detectable RNA editing sites is, although signiﬁcantly
so, very weakly associated with the ability to detect regulatory RNA
editing sites (ρ= 0.059, p = 5 × 10−4). Gene length and the number
Fig. 1. Pipeline to discover regulatory RNA editing sites. Editing sites annotated in RADAR database are matched to their host gene (A). The regulatory potential of each editing site is
discovered by testing the association between editing frequency and host RNA abundance (B). In this case, one editing site is signiﬁcantly positively associated with RNA abundance
(A1, maroon) and is classiﬁed as a potential regulatory editing site (C).
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the number of detected regulatory RNA editing sites (ρ= −0.066,
p = 1 × 10−4 for total gene length; and ρ= 0.028, p = 0.10 for the
number of Alu elements present in the gene body).Fig. 2. Landscape of regulatory RNA editing sites in LUAD. (A) Plot showing thedistribution of RN
line denotes q-value b 0.1 signiﬁcance threshold. Histogram of regulatory RNA editing sites' as
RNA editing siteswithin their RNAmolecule, and the top 50 are shown in (C). Edits are grouped
tumor and normal (D). Genes with high Tumor-normal regulatory RNA editing site correlatio
normal. The tumor-normal edit correlation is plotted against the number of regulatory edits in293 of the genes tested (8.5%) had N5 predicted regulatory RNA
editing sites, and the genes with the top 50 RNA editing sites are
shown in Fig. 2C. Regulatory relationships between ADAR and these
genes have only been investigated for a small number of these genes,A editing site-mRNAabundance correlation and the signiﬁcance of the association. The red
sociation to RNA abundance (B). Genes are ranked by the number of predicted regulatory
by their host gene and RNA editing site-RNA spearman correlations are compared between
n have regulatory RNA editing sites with similar regulatory potential in both tumor and
each host RNA molecule (E).
170 M.F. Sharpnack et al. / EBioMedicine 27 (2018) 167–175including CTSS (Stellos et al., 2016) andMDM2 (Zhang et al., 2016). Re-
markably our method was able to discover these established regulatory
relationships. CTSS is the best-studied example of gene regulation by
ADAR, and CTSS is the top hit according to our algorithm. For a full list
of genes with predicted regulatory RNA editing sites, please see Supple-
mentary Table 1. In addition,we investigated for possible enrichment of
putative regulatory relationships that are evolutionarily conserved.
1664/11319 (14.7%) and 4475/40957 (10.9%) of RNA editing sites
were signiﬁcant in rhesus or chimpand non-conserved, respectively, in-
dicating an enrichment of regulatory RNA editing sites in evolutionarily
conserved RNA editing sites (ﬁsher's exact test, p b 2.2e−16).
We next sought to discover which regulatory relationships are pres-
ent in both tumor and normal, and which are only present in tumor.
Since there are so many fewer normal samples, instead of comparing
statistical signiﬁcance of RNA editing sites between tumor and normal,
we compared the spearman correlations. For each gene, we calculated
the spearman correlation between the tumor and normal regulatory cor-
relations of all the RNA editing sites within that gene. A high tumor-nor-
mal correlation indicates that RNA editing mediated regulation of a gene
is not cancer speciﬁc. Of the 344 genes with at least 5 regulatory RNA
editing sites in tumors, 54/344 (16%) of these genes' edits had a positive
correlation between tumor and normal regulatory RNA editing sites of ρ
N 0.3, while 16 had a negative correlation of ρ b−0.3. 274/344 (80%) of
the regulatory edits are cancer-speciﬁc, especially in the genes with the
highest numbers of RNA editing sites (Fig. 2E).
The ADAR gene regulates themajority of RNA editing sites, while the
ADARB1 gene regulates a relatively small portion (Supplementary Fig.
2). Because ADAR and ADARB1 are upregulated and downregulated in
LUAD (Supplementary Fig. 3), respectively, the majority of RNA editing
sites is over-edited in tumors (Supplementary Fig. 1B). There are 756
differentially edited regulatory RNA editing sites across 242 differential-
ly expressed genes. Given that the majority of regulatory RNA editing
sites are positively associated with target RNA expression, one would
expect to see that over-edited genes also tend to be overexpressed. In
fact, 558/756 (74%) of the regulatory RNA editing sites are over-edited
while their host genes are overexpressed, and 93% of these RNA editing
sites are positively associated with RNA abundances in tumors. Of the
remaining RNA editing sites, 137/756 (18%) are over-edited with host
genes that are underexpressed. Unsurprisingly, 41% of these editing
sites are negatively associatedwith RNAabundances in tumors (Supple-
mentary Fig. 4). Together, these results show that ADAR overexpression
in tumors potentially controls cancer-speciﬁc differential expression of
hundreds of genes in LUAD.
An alternative hypothesis to RNA-editing mediated mRNA abun-
dance regulation is that mRNA abundances are merely associated with
RNA editing frequencies. In particular, ADAR is upregulated by interfer-
on signaling, which could also regulate genes that are edited by ADAR.
To isolate the effects of ADAR on its target genes, we compared the re-
sults from ADAR knockdown experiments on human B-Cells from
Wang et al. (2013) to our results in human LUAD. Interferon pathways
were not signiﬁcantly enriched among differentially expressed genes
after ADAR knockdown in their study. Wang et al. found 105 genes
with evidence of RNA editing had both alterations in RNA editing fre-
quency and mRNA abundance after ADAR knockdown via siRNA. 84/
105 (80%) of these genes also displayed evidence of editing in the
TCGA LUAD dataset, and 54/84 (64%) of the genes found to be regulated
by RNA editing were also putative regulated genes found by our meth-
od, representing a signiﬁcant enrichment.We performed a permutation
test to assess the signiﬁcance of this result by selecting 105 random sub-
sets of 1413 genes from the 3412 genes with evidence of editing. In
none of these iterations did a random gene set have a N64% overlap
with the set fromWang et al., a probability of b1 × 105 that the overlap
in our results and the results of Wang et al. occurred randomly. For ex-
ample, APOL1, CFLAR, DAP3, EIF2AK2, andMAVS were all putative regu-
lated genes found by both our method and Wang et al. For a full
comparison, see Supplementary Table 2.3.3. The APOL1 3′UTR ContainsMultiple Cancer-speciﬁc Regulatory Editing
Sites Controlled by ADAR
The CTSS and Apolipoprotein L1 (APOL1) genes had the largest num-
ber of predicted regulatory editing sites in LUAD (Fig. 2C). Since an
ADAR-CTSS regulatory relationship has already been established, we in-
vestigated the RNA editing patterns within the 3′ UTR of the APOL1
gene. APOL1 functions are not well characterized; however, it circulates
with the densest HDL subfraction, HDL3 (Monajemi et al., 2002). APOL1
variants have been implicated in chronic kidney disease (Parsa et al.,
2013), and they likely evolved due to their protective effects against T.
brucei rhodesiense infections (Vanhamme et al., 2003). APOL1 is upregu-
lated after interferon treatment or TLR3 stimulation via an IRF3-depen-
dent pathway, and high APOL1 expression in HIV-infected patients
with an interferon response contributes to chronic kidney disease
(Nichols et al., 2015). Despite its role in innate immunity and status as
an interferon-regulated gene, APOL1 has not yet been associated to
ADAR-mediated regulation.
APOL1 editing sites are frequently edited—21/74 (28%) sites have
N10% average editing frequency across all patients in LUAD (Fig. 3A).
71/74 (96%) editing sites in the APOL1 3′ UTR that are consistently
edited in LUAD have predicted regulatory roles, and editing of these
sites is positively associated with APOL1 RNA abundance (Fig. 3B). To
test whether ADAR or ADARB1 controls the editing of APOL1, the editing
frequencies of the predicted regulatory sites were correlated with the
RNA abundances of ADAR and ADARB1, respectively. The editing fre-
quency of the majority of these sites as well as APOL1 RNA abundance
was signiﬁcantly correlated with ADAR RNA abundance, indicating
that ADAR, not ADARB1, controls them (Fig. 3C–D). In addition, Wang
et al. (2013) found that after siRNA knockdown of ADAR, both APOL1
editing and gene expression decreased (Supplementary Table 2).
We next sought to discover if the regulation of APOL1 could be
cancer related. APOL1 is overexpressed in LUAD compared to
matched normal tissue samples (q b 0.1), and 26/74 (35%) of its
RNA editing sites show increased evidence of editing in cancer. In tu-
mors where APOL1 is over-edited, it also tends to be overexpressed
(Fig. 3E). Together, this evidence suggests that ADAR overexpression
and associated increased editing in LUAD potentially induces overex-
pression of APOL1.
Since our method provides nucleotide level regulatory hypotheses,
we performed a secondary structure analysis on the edited regions of
the APOL1 3′ UTR. We discovered that many of the regulatory RNA
editing sites change the predicted secondary structure, and several of
these regulatory RNA editing sites potentially effect RBP and microRNA
motifs, including numerous predicted PTBP1 binding sites (Supplemen-
tary Figs. 5–6). PTBP1 is overexpressed in tumors and correlated with
ADAR expression (Supplementary Fig. 7). However, the predictions of
RNA secondary structure, and RBP and microRNAmotifs are not perfect
and require functional validation.
3.4. RNA Editing of the APOL1 3′UTR is AssociatedWith Poor Overall Surviv-
al in Lung Adenocarcinoma
We next investigated the clinical importance of APOL1 in LUAD. We
separated the tumors into APOL1 high and APOL1 low based on the
mean APOL1 expression across all tumors and performed survival anal-
ysis (Fig. 4A). High APOL1 expression is signiﬁcantly associated with
poor prognosis (chi-square, p = 0.0066). In addition, high APOL1 ex-
pression is associated with poor survival using the survival meta-analy-
sis tool, precog (precog.stanford.edu) (Gentles et al., 2015), which
compiles the results of several gene expression datasets in lung adeno-
carcinoma (z = 3.37, p b 10−3). To determine if this effect was due to
RNA editing or other modes of APOL1 regulation, we then repeated
this survival analysis across all 74 editing sites in the APOL1 3′ UTR.
30/74 (41%) of the RNA editing sites within the 3′ UTR of APOL1
are signiﬁcantly associated with poor prognosis in LUAD (chi-square,
Fig. 3. The APOL1 3′ UTR containsmultiple regulatory editing sites controlled by ADAR. APOL1 3′ UTR contains several RNA editing sites which are edited at a very high frequency (A), and
most are signiﬁcantly positively correlated to APOL1 mRNA abundance (B). APOL1 editing frequencies (C) and RNA abundances (D) are both positively correlated with ADAR RNA
abundance. Fig. 3E shows for each patient the difference in chr22:36,662,382 editing frequency and APOL1 mRNA abundance between tumor and normal. APOL1 tends to be over-
edited and overexpressed in the same tumors (Rho = 0.27, p= 0.056). *q b 0.1.
171M.F. Sharpnack et al. / EBioMedicine 27 (2018) 167–175q-value b 0.1). Themost signiﬁcant edit (q=0.020)was also the closest
to the APOL1 coding region, located at chr22:36662161 (Fig. 4B). Editing
of this site is predicted to remove a kink in the secondary structure of
the APOL1 3′ UTR (Site 20 in Supplementary Fig. 5A–B). An alternativeFig. 4. Survival analysis of APOL1 RNA expression and APOL1 editing sites. Tumors are separated
into low vs. high chr22:36662161 editing frequency (B). P-values are calculated from Chi-Squahypothesis is that overall editing rates are prognostic, and not just spe-
ciﬁc sites; however, Paz-Yaacov et al. (2015) investigated this hypothe-
sis and did not report a signiﬁcant association between global editing
rates and overall survival in LUAD.into low vs. high APOL1 expression based on mean expression (A). Tumors are separated
re tests.
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lated Pathways
We performed functional enrichment (enrichr.org) (Chen et al.,
2013a; Kuleshov et al., 2016) of the genes with ﬁve or more regulatory
RNA editing sites in LUAD and found enrichment of apoptosis related
genes (Fig. 5A). In particular, we found that DFFA, CASP6, CASP8, CASP10,
MDM2, and CFLAR all contain multiple predicted regulatory RNA editing
sites (shown in parentheses). These genes are inhibitors of the FAS ligand
induced apoptotic pathway and except for MDM2 (Zhang et al., 2016),
have not yet been linked to ADAR-mediated regulation (Fig. 5B).
In addition,we foundenrichment of 2 pathways related to the innate
immune functions of ADAR (signiﬁcant by p-value but not aftermultiple
hypothesis correction). Most importantly, EIF2AK2 (PKR), EIF2S3
(EIF2γ), DDX58 (RIG-I) and MAVS contain numerous regulatory edits
(Fig. 2). These proteins are all interferon stimulated, and act in concert
to inhibit the replication of dsRNA viruses. PKR phosphorylates EIF2α
and leads to inhibition of the EIF2 complex, of which EIF2γ is the core
subunit (Carpenter et al., 2014) (Fig. 5C). Inhibition of the EIF2 complex
halts translation and leads to stress granule responses (Mccormick and
Khaperskyy, 2017). Our results predict that ADAR positively regulates
these genes via editing of their 3′ UTR's. In addition, Li Y., et al. noted
that ADAR knockdown in interferon stimulated human LUAD A549
cells prevented the expected upregulation of EIF2AK2, suggesting that
ADAR is necessary for interferon-mediated EIF2AK2 expression. The au-
thorswere unable to explain thisﬁnding; however, ourmethod predicts
that ADAR upregulates EIF2AK2 via editing of its 3′ UTR (Li et al., 2017).
Interlinked with stress granule formation in the innate immune re-
sponse to dsRNA, is theMDA5-MAVS complex.MDA5 binds to unedited
dsRNA molecules and is the ﬁrst step of the dsRNA antiviral interferon
response (Wu et al., 2013). The MAVS protein binds to MDA5 and
forms ﬁlaments on themitochondrial membrane and acts as an adaptor
in this process (Hou et al., 2011).MAVS contains both positive and neg-
ative regulatory RNA editing sites in LUAD. In fact, RNA editing sites
within theMAVS 3′ UTR that have higher mean editing frequency tendFig. 5.RNA-editing regulated genes in LUAD are enriched in apoptosis and innate immune-relat
editing sites (A). Pathway diagram showing the genes that are enriched in the apoptosis (B) and
negative regulation by ADAR-mediated RNA editing, respectively. TheMAVS protein is colored i
3′ UTR.to be more negatively associated withMAVS abundance (Rho =−0.57,
p = 6.6 × 10−11, Supplementary Fig. 8A). This suggests that there is a
more complex regulatory process governingMAVS RNA abundance. This
pattern is present in other RNAmolecules withmultiple negative regula-
tory sites, such as LIMD1 and VHL (Supplementary Fig. 8B\\C).
It is important to note that the same bias that has caused enrichment
in positive regulation by RNA editing in a majority of regulatory RNA
editing sites may also bias the pathway enrichment analysis we per-
formed. In addition, we performed an analysis to uncouple the upstream
effects of interferon pathway expression on potential regulatory RNA
editing sites.We split patients into four groups based on interferon path-
way expression and RNA editing levels at each RNA editing site, and then
compared the gene expression for genes with potential regulatory RNA
editing sites between these groups. We tested 6139 regulatory RNA
editing sites for potential regulation by RNA editing independent of in-
terferon pathway expression. 2494 regulatory RNA editing sites were
measured in a sufﬁcient number of tumors (N N 200) for comparison,
and we found evidence of widespread regulation of their host genes by
RNA editing independent of interferon pathway expression (full data
available in Supplementary Table 3). In addition, there are numerous
genes whose expression is both independently associated with RNA
editing levels and interferon levels. For example, EIF2AK2 is highly
expressed in tumors with high 3′ UTR RNA editing and high interferon
pathway expression; moderately expressed in tumors with either high
3′ UTR RNA editing or high interferon pathway expression; and lowly
expressed in tumors with low 3′ UTR RNA editing and low interferon
pathway expression (Supplementary Fig. 9). This result is consistent
with the ﬁnding by Li et al. that both ADAR and interferon expression
are necessary to induce EIF2AK2 expression (Li et al., 2017).
3.6. ADARCopyNumber is Anti-correlatedWith Immune and Apoptotic Sig-
natures in Lung Adenocarcinoma
To investigate the role of ADAR in immune and apoptotic pathways
we calculated the pathway enrichment in each tumor sample usinged genes. Biocarta pathway enrichments of geneswith 5 ormore predicted regulatory RNA
innate immune-related pathways (C). Blue and red colored proteins indicate positive and
n both blue and red because there are both positive and negative regulatory edits within its
173M.F. Sharpnack et al. / EBioMedicine 27 (2018) 167–175single sample gene set enrichment analysis (ssGSEA) (Barbie et al.,
2009) on the 50 MSigDB hallmark gene sets (Liberzon et al., 2015).
ADARwas initially identiﬁed as an oncogene due to its frequent ampliﬁ-
cation in several human cancers (Han et al., 2015). As such, we investi-
gated the association between ADAR CN and pathway activity, and
found that for many pathways, the association between ADAR CN and
pathway activity is the opposite of the association between ADAR RNA
abundance and pathway activity, in spite of a high ADAR CN-RNA
correlation (ρ=0.50). We found that ADAR CN is strongly negatively
associated with apoptotic activity in LUAD (Fig. 6A). ADAR RNA
abundance was not correlated with the apoptosis pathway in
LUAD. Similarly for immune related measures, ADAR RNA is positive-
ly correlated with the interferon alpha pathway but ADAR CN is neg-
atively associated with it (Fig. 6A). One possible explanation for this
ﬁnding is that separate ADAR isoforms have opposing effects on im-
mune and apoptotic pathways. The ADAR p150 isoform contains
exon 1 while ADAR p110 does not; however, the exons are too highly
correlated to distinguish between their expression. The lowest cor-
relation between exon 1 and exons 2–15 expression is 0.77. There-
fore, we cannot distinguish between the expression of ADAR p150
or ADAR p110 in this cohort.
Given the ﬁnding that ADAR CN is negatively associated with signa-
tures of apoptosis and innate immunity, we investigated the association
between ADAR CN and immune inﬁltrates. We ﬁrst downloaded tumor
purity and immune inﬁltrate data fromAran et al. (2015) and then used
the TIMER app (https://cistrome.shinyapps.io/timer/) (LiLi et al., 2016)
to test for associations with speciﬁc immune cell types. We found that
ADAR CN is signiﬁcantly negatively associated with all markers of im-
mune inﬁltrate and tumor purity used in Aran et al. (Fig. 6A). In fact,
given the strength of the association, we searched the entire genome
for genes whose copy numbers negatively correlate with immune inﬁl-
trate signatures in LUAD. It was found that genes most negativelyFig. 6. ADAR ampliﬁcation is associated with decreased immune cell concentrations in lung ad
relevant pathway, tumor purity, and immune inﬁltrate signatures. The TIMER app was used
status (B). Tumors with ADAR CN gain or ampliﬁcation had evidence of signiﬁcantly fewer C
slides were scored for their lymphocyte concentrations on a grade 0–3 (C). Signiﬁcance codesassociated with immune inﬁltrates reside on the 1q21 locus (Supple-
mentary Figs. 10–11), and form a coherent amplicon that includes
ADAR (Supplementary Fig. 11B).We further discovered that ADAR geno-
mic gains and ampliﬁcations have signiﬁcantly fewer predicted concen-
trations of CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and
dendritic cells (Fig. 6B). It is possible that other genes located at the
1q21 locus mediate this effect, and the causal role of ADAR in immune
exclusion requires functional validation.
To conﬁrm this ﬁnding, we graded LUAD tumors based on their ap-
parent inﬁltration of different immune cell types on a 0–3 scale in histo-
logical slides from TCGA (http://cancer.digitalslidearchive.net)
(Gutman et al., 2013). We selected 97 LUAD tumors, 45 of which had
no evidence of ADAR ampliﬁcation, and 52 of which had high ADAR
copy number, and conducted the experiment with no knowledge of
the ADAR CN status of these tumors. We were able to visually estimate
neutrophil, lymphocyte, and macrophage inﬁltrations, as well as necro-
sis. While no apparent pattern was observed for neutrophils, necrosis,
and macrophages, there was a trend towards fewer lymphocytes in
ADAR CN high tumors (t-test, p= 0.01) (Fig. 6C).
The fundamental question is, does RNA abundance regulation by
RNA editing account for the differences between ADAR RNA and copy
number pathway enrichments? We looked at the independent effects
of interferon pathway expression and ADAR copy number on editing
levels, by doing a differential editing experiment with one of the vari-
ables controlled. The differences in editing between copy number high
vs. low and interferon high vs. low are extremely similar (ρ= 0.76).
In other words, whether ADAR is upregulated by interferon or copy
number ampliﬁcations doesn't matter, the same RNA editing sites are
changed. This is evidence against RNA abundance regulation by RNA
editing as being the driving force behind the intransitive relationship
that we see between ADAR RNA, copy number, and interferon
expression.enocarcinoma. Fig. 6A shows the correlation between ADAR RNA and CN abundances and
to estimate immune cell subtype concentrations in LUAD tumors with known ADAR CN
D8+ T Cells, CD4+ T Cells, Macrophages, Neutrophils, and Dendritic Cells. Histological
for (B): 0 ≤ *** ≤ 0.001 ≤ ** ≤ 0.01 ≤ * ≤ 0.05.
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Despite the prevalence of A-I RNA editing of non-coding regions
within mRNAs, very little research has been done to elucidate the
functions of these alterations in cancer. To remedy this situation,
we perform a comprehensive analysis of RNA abundance regulation
by RNA editing. These results are a resource to better understand
the regulation of thousands of genes, and a full list of genes with reg-
ulatory edits is provided in Supplementary Table 1. Despite conﬁr-
mation of some of these results in an ADAR knockdown
experiment, further functional validation is necessary to conﬁrm
the causality of these regulatory relationships. This method can be
run on any dataset of matched RNA abundance and RNA editing fre-
quencies, and it provides nucleotide level information to better guide
validation experiments. For example, our method could be used as a
resource to understand the RNA regulatory landscape of normal tis-
sues from data published by (Tan et al., 2017). A limitation of our
method is a lesser ability to detect negative compared to positive
regulatory relationships. Detection of negative relationships may re-
quire time-lapse functional experiments, where the degradation of
heavily edited transcripts can be tracked in real time.
In addition, an integrative analysis of ADAR CN and pathway en-
richments showed that despite the high correlation between ADAR
CN and RNA, ADAR copy number and RNA tend to have opposite rela-
tionships with immune and apoptosis pathways. ADAR is an interfer-
on stimulated gene (Pestal et al., 2015), and positive correlation
between ADAR RNA and immune regulated pathways could point to-
wards ADAR being upregulated in a compensatory fashion by inter-
feron stimulation. Sensing of aberrant DNA or RNA, such as by toll
like receptors and MDA5 can cause this interferon stimulation.
When ADAR is genomically ampliﬁed, these patterns could imply
that unregulated increases in ADAR expression constitutively repress
interferon in the tumor microenvironment and drive tumor immune
evasion. It has been shown previously that poly(I:U) dsRNA is sufﬁ-
cient to decrease interferon responses (Vitali and Scadden, 2010).
In addition, this ﬁnding raises the possibility of a synergism between
ADAR inhibition and immunotherapies. Three studies recently dis-
covered that DNA methylation inhibitors induce an interferon re-
sponse via expression of aberrant dsRNA's, and can even induce
sensitivity to immune checkpoint therapies (Chiappinelli et al.,
2015; Roulois et al., 2015; Wrangle et al., 2013). In a similar manner,
ADAR inhibition could be a new addition to combination
immunotherapies.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2017.12.005.
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